Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Starpharma has announced the signing of a new agreement with Eli Lilly, under which Starpharma’s dendrimer drug delivery technology will be applied to enhance compounds in Lilly’s human pharmaceutical portfolio.
Subscribe to our email newsletter
Under the terms of the agreement, Lilly will fund a collaborative research and development program with the aim of creating improved drugs incorporating SPL’s proprietary delivery technology, and will be commercialised by Lilly.
Reportedly, the agreement relates to the delivery of certain human pharmaceuticals. It is separate and additional to the contract signed in May 2009, in which it was agreed that Starpharma and Elanco (Lilly’s animal health division) would work together to develop new animal health products with enhanced properties. The Elanco collaboration continues.